AMNIMO
23.3.2020 07:02:05 CET | Business Wire | Press release
amnimo Inc. (Headquarters: Musashino City, Tokyo; President & CEO: Koichi [Casey] Taniguchi; hereafter, “amnimo”) starts developing an industrial-use LTE gateway, “Edge Gateway,” which is equipped with rich computing resources and a high level of robustness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005056/en/
IoT is a mechanism by which a variety of devices are connected to each other via the network or the cloud service; these devices exchange information with each other. Recently, numerous approaches to the use of industrial-use IoT (IIoT) have been evolving in all types of industries. As IIoT continues to proliferate, examples of user work process improvements are increasing, but at the same time, we are witnessing operational issues such as suppressing failures in harsh external environments and being able to remotely deal with failures without going to the site. There have also been requests to process large volumes of data, such as video, using Edge in an advanced manner.
To resolve such issues, amnimo is developing the “Edge Gateway,” which is optimized for IIoT. The objective is to equip the Edge Gateway with LTE communication features that can be used in a wide variety of industries; in particular, to develop an optimal design for use in surveillance-camera systems.
[Characteristics of the Edge Gateway]
- Wide operating temperature range and power voltage range. Equipped with power circuits that are robust against noise and sudden outages, it has features for automatic recovery in case of a failure. This helps achieve stable operation even in harsh outdoor environments.
- Equipped with 2 GB of RAM and 32 GB eMMC for program storage space as the standard configuration, it can also be operated using a 2-TB SSD (Solid State Drive), enabling large-volume video data to be stored within the Edge Gateway.
- Equipped with a power-supply function for PoE(*1) compatible devices, it can be directly connected to a maximum of four IP cameras without using a PoE hub.
- The communication modules can accommodate two types of plastic SIM cards and eSIMs for a maximum of four different carrier SIMs, enabling the user to bypass communication failures by switching SIMs at high speeds in cases of emergency.
- Customer app development is possible on the Ubuntu OS; in addition, software development kits are provided for partners.
- Equipped with a VMS (Video Management System (*2)) as standard, simplifying the process of constructing small-, medium-, and large-scale surveillance systems.
- An extension port slot is internally provided in the Edge Gateway, enabling smooth addition of future functional extensions.
*1 Power over Ethernet: Specification wherein power is provided to the connected device(s) using Ethernet communication cables.
*2 System for saving and managing video captured using a surveillance camera.
In addition, we are developing a “device management system” to resolve issues related to operation on IIoT devices, such as the Edge Gateway. This device management system is a cloud service that enables initial configuration of IIoT devices, remote configuration and firmware updates, management of installation location, equipment life monitoring, log collection during operation, problem analysis and replacement, and transfer of configuration data for troubleshooting, thereby reducing the burden on the operator.
amnimo provides customer support for IIoT service and surveillance-camera systems, with the following objectives: “fast response and resolution for customer issues,” “value creation and innovation,” and “aim to grow with partners.”
About amnimo
amnimo was formed as a solely owned subsidiary of Yokogawa Electric Corporation as a new business to provide Industrial Internet of Things (IIoT) services in May 2018. With an excellent mobility, amnimo makes a swift decision and develops its business in a rapidly changing market. amnimo strengthens collaboration with customers and partner companies in various fields and countries to create new shared values by leveraging IIoT technologies.
To learn more, please visit https://amnimo.com/en/
The company names, organization names, and product names used in the document are registered trademarks or trademarks of the relevant organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200322005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom